HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe

ResMed to Educate Heart Failure Nurses at AAHFN 2006

April 1, 2006 by HME Business

SAN DIEGO &#151 ResMed announced further progress in its ongoing efforts to improve the lives of sleep apnea patients with cardiovascular disease (CVD). As part of this initiative, ResMed will attend the American Association of Heart Failure Nurses Annual Meeting to educate heart failure nurses on new technologies and methods for treating sleep apnea and improving therapy compliance in CVD patients.


A special focus for the exhibition will be a luncheon presentation about the VPAP Adapt SV&#153, a therapy device that received FDA clearance for the treatment of central sleep apnea (CSA), mixed apnea and periodic breathing such as Cheyne-Stokes respiration (CSR).
The comorbidity of SDB and CVD has been cited in peer reviewed publications in The New England Journal of Medicine, Circulation, European Heart Journal and others. These publications show sleep apnea prevalence in CVD patients to be approximately 50 percent. Research also shows that treating sleep apnea can significantly improve treatment outcomes for CVD patients. Patient compliance, however, is essential to the success of sleep apnea treatment.


To address compliance issues, ResMed has been working to develop new solutions for CVD patients with sleep apnea. The VPAP Adapt SV effectively treats difficult forms of SDB-CSA, mixed apnea and CSR-in a way that is comfortable and clinically effective for patients in their homes.


“Previously, our goal was to educate health care professionals on the high prevalence of sleep apnea among CVD patients,” stated Mick Farrell, vice president of marketing, Americas. “Now that the health care community recognizes the severe impacts of sleep apnea on their patients, our goal has shifted toward helping them treat sleep apnea effectively. The VPAP Adapt SV represents a significant breakthrough for patients with CSA, mixed sleep apnea and CSR, and fulfills the need of the medical community for a comprehensive treatment solution for these patients.”


ResMed will exhibit at booth #1765 at the AAHFN 2006 in Miami. The session takes place June 22-25. ResMed will host a special luncheon presentation on Thursday, June 22, from 10:30 a.m. to noon. For more information, contact Brooke Harding at ResMed Corp at
(858) 746-2400 x2579 or [email protected]. Visit the company’s Web site at www.resmed.com.

Related Articles Read More >

LUX Infusion Acquires Infuse IQ
Florida-based LUX Infusion provides home infusion and ambulatory infusion services.
September Wellness Challenge to Benefit NHIF Research Grant Program
The National Home Infusion Foundation is encouraging industry professionals to care for themselves and others.
Increased Home Infusion Demand Challenges Home Health Care Providers
More complex patients are being discharged to their homes, but is current home infusion policy keeping up?
Cardinal Health Praises at-Home Solutions’ Efficiency, Growth in Q4 2026 Earnings Call
In July, the at-Home Solutions segment announced two acquisitions in one day.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe